Induction of cellular immunosuppression by the human papillomavirus type 16 E7 oncogenic protein

Biomedicine and Pharmacotherapy

Volumn 53, Issue 7, 1999, Pages 323-328

  Le Buanec, H ^a   Lachgar, A ^a   D'Anna, R ^a   Zagury, J F ^a   Bizzini, B ^a   Bernard, J ^b   Ittele D ^b   Hallez, S ^c   Giannouli, C ^c   Burny, A ^c   Zagury, D ^a  

^a SORBONNE UNIVERSITÉ   (France)

^b INSTITUT JEAN GODINOT   (France)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Cervical carcinoma; E7 protein; HPV vaccine; Human papillomavirus; Immunosuppression

Indexed keywords

ALPHA INTERFERON; VIRUS PROTEIN;

ANTIGEN PRESENTING CELL; ARTICLE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; VIRUS IMMUNITY; WART VIRUS;

EID: 0033178028     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)88505-4     Document Type: Article

References (24)

1. Folkman J The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3 : 65-71.
2. Karpati RM, Banks SM, Malissen B, Rosenberg SA, Sheard MA, Weber JS, et al. Phenotypic characterization of murine tumor infiltrating T-lymphocytes. J Immunol 1991; 146 : 2043-51.
3. Young MR, Wright MA, Lozano Y, Matthews JP, Benefield J, Prechel MM. Mechanisms of immune suppression in patients with head and neck cancer: Influence on the immune infiltrate of the cancer. Int J Cancer 1996; 67 : 333-8.
4. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13 : 1-27.
5. Scheffner M, Munger K, Byrne JC, Howley PM. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 1991; 88 : 5523-7.
6. Madrigal M, Janicek MF, Sevin BU, Perras J, Estape R, Penalver M, et al. In vitro antigen therapy targeting HPV-16 E6 and E7 in cervical carcinoma. Gynecol Oncol 1997; 64 : 18-25.
7. Scheffner M, Munger K, Huibregtse JM, Howley PM. Targeted degradation of the retinoblastoma protein by human papillomavirus E7-E6 fusion proteins. EMBO J 1992; 11 : 2425-31.
8. Elbel M, Carl S, Spaderna S, Iftner T. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. Virology 1997; 239 : 132-49.
9. Nasseri M, Gage JR, Lorincz A, Wettstein FO. Human papillomavirus type 16 immortalized cervical keratinocytes contain transcripts encoding E6, E7, and E2 initiated at the P97 promoter and express high levels of E7. Virology 1991; 184 : 131-40.
10. Ruben S, Perkins A, Purcell R, Joung K, Sia R, Burghoff R, et al. Structural and functional characterization of human immunodeficiency virus tat protein. J Virol 1989; 63 : 1-8.
11. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993; 67 : 277-87.
12. Viscidi RP, Mayur K, Lederman HM, Frankel AD. Inhibition of antigen induced lymphocyte proliferation by Tat protein from HIV-1. Science 1989; 246 : 1606-8.
13. Zagury JF, Lachgar A, Bernard J, Bizzini B, Astgen A, Lecoq H, et al. A critical role of Tat and IFNα in the HIV1-induced immunosuppression leading to AIDS. Cell Pharmacol AIDS Sci 1996; 3 : 97-103.
14. Zagury D, Lachgar A, Chams V, Fall LS, Bernard J, Zagury JF, et al. Interferon-α and Tat involvement in the immunosuppression of uninfected T-cells and C-C chemokine decline in AIDS. Proc Natl Acad Sci USA 1998; 95 : 3851-6.
15. Friedl F, Kimura I, Osato T, Ito Y. Studies on a new human cell line (SiHa) derived from carcinoma of uterus. I. Its establishment and morphology. Proc Soc Exp Biol Med 1970; 135 : 543-5
16. Hallez S, Detremmerie O, Giannouli C, Thielemans K, Gajewski TF, Burny A, et al. Interleukin-12-secreting human papillomavirus type 16 transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int J Cancer 1999; 81 : 428-37
17. Sallusto F, Lanzaveechia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor alpha. J Exp Med 1994; 179 : 1109-18.
18. Hawkes R, Niday E, Gordon J. A dot-immunobinding assay for monoclonal and other antibodies. Ann Biochem 1982; 119 : 142-7.
19. Rubinstein S, Familletti PC, Pestka S. Convenient assay for interferons. J Virol 1981; 37 : 755-8.
20. + blood dendritic cells are potent producers of IFNα in response to in vitro HIV-1 infection. J Immunol 1994; 152 : 4649-62.
21. Fisher SG, Benitez-Bribiesca L, Nindl I, Stockfleth E, Muller M, Wolf H, et al. The association of human papillomavirus type 16 E6 and E7 antibodies with a stage of cervical cancer. Gynecol Oncol 1996; 61 : 73-8.
22. De Bruijn ML, Schuurhuis DH, Vierboom MP, Vermeulen H, de Cock KA, Ooms ME, et al. Immunization with human papillomavirus type 16 (HPV16) oncoprotein-loaded dendritic cells as well as protein in adjuvant induces MHC class I restricted protection to HPV-16-induced tumor cells. Cancer Res 1998; 58 : 724-31.
23. Le Buanec H, Lachgar A, Bizzini B, Zagury JF, Rappaport J, Santagostino E, et al. A prophylactic and therapeutic AIDS vaccine containing as a component the innocuous Tat toxoid. Biomed Pharmacother 1998; 52 : 431-5.
24. Chen L, Mizuno MT, Singal MC, Hu SL, Galloway DA, Hellstrom I, et al. Induction of cytotoxic T-lymphocytes specific for a syngeneic tumor expressing the E6 oncoprotein of human papilloma virus type 16. J Immunol 1992; 148 : 2517-21.